Nurtec ODT (rimegepant ODT) / Pfizer - LARVOL DELTA

Identification and validation of NETs-associated biomarkers in osteoporosis with diabetes. (PubMed, Sci Rep) - "Drugs such as rimegepant and eptinezumab were associated with biomarkers. This preliminary study suggests that S100A12 and SLC25A37 may serve as candidate biomarkers associated with NETs in osteoporosis with diabetes, providing a preliminary theoretical foundation for future larger-scale studies."

Biomarker • IO biomarker • Journal • Diabetes • Metabolic Disorders • Osteoporosis • Rheumatology • Type 2 Diabetes Mellitus • MIR146A • MIR7 • S100A12 • SLC25A3 • SLC25A37 • SLC5A7 • XIST

Denmark Announces End of Vydura Conditional Reimbursement (NAVLIN DAILY) - "The Danish Medicines Agency has announced that patients using the migraine medicine Vydura (rimegepant) will soon need to apply for individual reimbursement in order to receive financial support for the treatment...."

Reimbursement • Migraine

RAG-MPDAC: Rimegepant Combined With AG Chemotherapy As First-Line Treatment For Metastatic Pancreatic Ductal Adenocarcinoma (clinicaltrials.gov) - P1/2 | N=30 | Not yet recruiting | Sponsor: Xiuchao Wang

New P1/2 trial • Oncology • Pancreatic Cancer • Pancreatic Ductal Adenocarcinoma

Delayed urticaria during treatment with anti-CGRP monoclonal antibodies in migraine. (PubMed, Headache) - "Anti-CGRP mAb-associated urticaria in this case series was delayed and likely non-immunoglobulin E (non-IgE)-mediated. Our experience supports that in selected patients with delayed urticaria, individualized management, including H1 antihistamine premedication, may allow continuation of effective migraine prophylaxis. Larger cohorts are needed to identify risk factors and to inform general management recommendations."

Journal • Allergy • Cardiovascular • CNS Disorders • Dermatology • Immunology • Migraine • Pain • Urticaria

Post-marketing safety of CGRP monoclonal antibodies and gepants: A systematic review of spontaneous reporting system data. (PubMed, Headache) - "This systematic review confirms that CGRP inhibitors have a manageable yet complex safety profile. It distinguishes rare, serious cerebrovascular events (RCVS, CeAD) associated with some mAbs but not with gepants, as well as shared adverse effects such as Raynaud's phenomenon and alopecia. Significant heterogeneity in safety profiles-from erenumab's pronounced constipation SDR to zavegepant's unique dysgeusia-challenges the view of CGRP inhibitors as a monolithic category. These findings provide a clear rationale for personalized risk assessment, enabling clinicians to tailor treatment to individual patient profiles."

Journal • P4 data • Review • Alopecia • Cardiovascular • CNS Disorders • Constipation • Fatigue • Gastroenterology • Gastrointestinal Disorder • Immunology • Migraine • Pain • Rheumatology • Vascular Neurology • ROR1

Real-world Effectiveness of Preventive Rimegepant: Longitudinal Outcomes Across Extended Follow-up Intervals (AAN 2026) - "Models adjusted for sex, age, BMI, and concurrent onabotulinumtoxinA exposure. Preventive rimegepant was associated with early reductions in MHD, WPI, and API, while MSD and MIDAS improvements emerged later. These findings provide real-world data of early symptomatic benefit and evolving functional gains with rimegepant. Observed improvements reflect while-on-treatment outcomes; high discontinuation limits inference on sustained benefit."

Clinical • Real-world • Real-world effectiveness • Real-world evidence • CNS Disorders • Migraine

Headache & Facial Pain Section Poster Tour (AAN 2026) - "If you are interested in attending,visit the poster hall and look for the tour guide holding the yellow Poster Tour sign. Featured abstracts:Patient-reported Outcomes Through 12-weeks of Double-blind Rimegepant Treatment for the Prevention of Episodic Migraine in Adults with Prior Inadequate Response to Oral PreventativesPatient Treatment Satisfaction with OnabotulinumtoxinA Versus Topiramate for Chronic MigraineAssociation Between Midlife Migraine and Dementia During over 40 Years of Follow-up in a Large U.S. Healthcare DatabaseEfficacy of Vestibular Rehabilitation in the Management of Vestibular Migraine: a Systematic Review and Meta-analysisPhysical Therapist-delivered Biofeedback-assisted Relaxation for Migraine: A Qualitative Analysis of Results from a Pilot Randomized Controlled TrialDaily Light Exposure Habits of Youth with Migraine and its Association with Headache Frequency"

Alzheimer's Disease • CNS Disorders • Dementia • Migraine • Pain

RACIAL AND ETHNIC DISPARITIES IN ADOPTION OF NOVEL CGRP THERAPIES FOR MIGRAINE PREVENTION: A RETROSPECTIVE COHORT STUDY USING THE KOMODO RESEARCH DATASET (ISPOR 2026) - "OBJECTIVES: To evaluate racial disparities in uptake of calcitonin gene-related peptide (CGRP) therapies (Erenumab, Fremanezumab, Galcanezumab, Eptinezumab, Atogepant, or Rimegepant) for migraine prevention among adults in the United States. This retrospective cohort study was conducted using the Komodo Research Dataset and Komodo Race and Ethnicity. CGRP initiation remained low across all groups. Although median time to initiation was similar, cumulative incidence patterns suggest differential adoption over time."

Retrospective data • CNS Disorders • Migraine • Pain

COMPARING THE DISEASE BURDEN OF MIGRAINE BETWEEN USERS OF CGRP MONOCLONAL ANTIBODIES AND PREVENTIVE GEPANTS (ISPOR 2026) - "Analysis included participants that: (1) Experienced migraine or migraine headaches in the past 12 months; (2) Physician diagnosis of migraine; and (3) Currently using CGRP mAbs (erenumab, fremanezumab, eptinezumab, or galcanexumab) or preventive gepants (rimegepant or atogepant). In a national survey of general US adults, CGRP mAbs users reported fewer migraines and headache days than those on preventive gepants (though still greater than the meaningful clinical goal of ≤4 days per month), but experienced lower treatment efficacy, greater mental health burden and migraine-related disability. These findings underscore the need to address psychological and functional burden among patients on migraine preventives."

CNS Disorders • Depression • Migraine • Mood Disorders • Pain

Risk Stratification of Hypertension Induced by CGRP Antagonist in Migraine Treatment: A Retrospective Observational Analysis (AAN 2026) - "With the growing use of the Gpant class of drugs and other CGRP inhibitors in clinical settings, it is critical to determine which populations are most at risk for developing this side effect.Design/ 250 patients prescribed any CGRP antagonist, including erenumab, fremanezumab, galcanezumab, eptinezumab, and the gepants (ubrogepant, rimegepant, atogepant, zavegepant).Variables extracted included: age at start, sex, and body mass index (BMI). Hypertension following CGRP initiation is an early event, occurring within the first few months.Once developed, hypertension tends to persist, with no new cases after 3 months. The pattern is similar across drug classes, indicating that risk is likely related to the CGRP pathway blockade rather than a specific molecule."

Retrospective data • Cardiovascular • Chronic Kidney Disease • CNS Disorders • Diabetes • Hypertension • Metabolic Disorders • Migraine • Nephrology • Obstructive Sleep Apnea • Pain • Renal Disease • Respiratory Diseases • Sleep Disorder

CGRP Monoclonal Antibodies vs Gepants: Risk of Vascular Outcomes: A TriNetX Multicenter Electronic Medical Record Analysis (AAN 2026) - "Real-world evidence comparing vascular risk between mAbs and gepants remains limited.Design/ We conducted a cross-sectional study using the TriNetX® database to identify adults with migraine (ICD-10 G43) prescribed CGRP mAbs (erenumab, galcanezumab, fremanezumab, eptinezumab) or gepants (atogepant, rimegepant). CGRP mAbs were linked to greater vascular risk than gepants. Elevated risk among never-users may reflect underlying clinical characteristics, prescribing patterns, and possibly a protective effect of CGRP inhibitors. These findings stress the need for prospective studies to clarify causality and guide vascular safety monitoring."

Clinical • Cardiovascular • CNS Disorders • Hypertension • Migraine

Emgality Transfer into Breast Milk (AAN 2026) - "Monoclonal antibodies used in other neurological conditions (such as rituximab, ocrelizumab) have previously shown low transfer into breast milk. An oral CGRP receptor antagonist, rimegepant, has a low RID in human breast milk; until this study, no published data were available on the transfer of galcanezumab, an injectable CGRP monoclonal antibody, into human breast milk. Understanding the transfer into breast milk of highly effective migraine therapies such as galcanezumab is crucial to providing women safe, effective treatments for headaches, especially during the postpartum period when at high risk of migraine recrudescence."

CNS Disorders • Migraine

MAMBO-II: Randomized Cross-Over Experimental Trial of Treatment with Sumatriptan vs. Rimegepant During Nitroglycerin (NTG)-Induced Headache in Patients with Episodic Migraine for the Determination of Molecular and Clinical Biomarkers (MAMBO II Study). (clinicaltrialsregister.eu) - P4 | N=24 | Recruiting | Sponsor: Fundacio Hospital Universitari Vall DHebron Institut De Recerca | Not yet recruiting ➔ Recruiting

Biomarker • Enrollment open • CNS Disorders • Migraine • Pain

Efficacy and safety of rimegepant 75 mg orally disintegrating tablet for the acute treatment of chronic rhinosinusitis in adults: Results from a multicenter, randomized, placebo-controlled, phase 2/3 trial. (PubMed, PLoS One) - P3 | "Although no treatment differences were identified, the findings could contribute to the design of future clinical trials and better disease understanding. Trial registration ClinicalTrials.gov NCT05248997."

Journal • P2/3 data • Immunology • Inflammation • Nasal Polyps • Otorhinolaryngology • Pain • Respiratory Diseases • Sinusitis

Reasons for Discontinuing Triptans Among Current Users of Rimegepant for the Acute Treatment of Migraine in the CONFIDENCE Study (AAN 2026) - P | "Insufficient pain reduction, side effects, not working as well as it used to, and not working quickly enough were common reasons for triptan lapse. Side effects were reported by ~50% of participants, irrespective of how many triptans had lapsed. The other three most common reasons were more frequently reported in participants with more lapsed triptans."

CNS Disorders • Migraine • Pain

Safety and Effectiveness of Rimegepant for Acute Treatment of Migraine in Adults Unsuitable for Triptan Use: Results from a 12-week Open-label Extension Phase. (AAN 2026) - P4 | "In triptan-unsuitable adults, RIM 75 mg ODT PRN for up to 12 weeks demonstrated favorable safety, stable population-level effects across repeated attacks, and fewer MMDs."

Clinical • CNS Disorders • Migraine • Pain

Network Meta-analysis of Atzumi (STS101) Dihydroergotamine Nasal Powder Versus Modern Oral and Intranasal Agents for the Acute Treatment of Migraine (AAN 2026) - "In contrast, zavegepant 10 mg IN, ubrogepant 50 mg PO, and rimegepant 75 mg ODT achieved PF RRs of 1.49, 1.52, and 1.46, respectively, while sumatriptan 100 mg PO remained highest (1.88 [1.64–2.15]). Atzumi (STS101) showed sustained efficacy beyond 3 hours with excellent tolerability, offering a safe non-oral option for acute migraine; overall study quality was high with low ROB 2.0."

Retrospective data • CNS Disorders • Migraine • Pain

Understanding Real-world Perspectives of Healthcare Providers on Short-term Prevention for Migraine and Rimegepant Treatment Use by Patients: Findings from Cross-sectional Surveys (AAN 2026) - "HCPs support discussing STP with patients who have predictable triggers/specific situations to prevent a migraine attack. Findings suggest that both HCPs and patients perceive the potential benefits of STP and flexible use of rimegepant for STP."

Clinical • Real-world • Real-world evidence • CNS Disorders • Migraine • Pain

Prospective Open-label Pilot Study of Rimegepant as a Treatment for Cluster Headache (AAN 2026) - "Rimegepant may be helpful in a subset of cluster headache patients. Larger studies are needed."

Clinical • Chronic Cluster Headache • Pain

Desensitization Protocol in Patients with Immediate Eptinezumab Hypersensitivity: A Case Series (AAN 2026) - "She was treated in the emergency department (ED), requiring epinephrine, and discharged on prednisone and anti-histamines, but returned the following day with recurrent throat swelling and urticaria. She was switched to rimegepant 75 mg every other day but also experienced shortness of breath and urticaria...She had previously trialed multiple anti-seizure medications, anti-depressants, anti-hypertensives, other anti-CGRP medications, memantine, cyproheptadine, nerve blocks, and neuromodulation...She tolerated a three-bag 12-step eptinezumab desensitization with only subjective symptoms, managed with diphenhydramine... Eptinezumab can induce hypersensitivity reactions in 1-4% of patients. Desensitization may allow patients to receive eptinezumab when no equally effective alternatives are available."

Clinical • CNS Disorders • Cough • Epilepsy • Immunology • Migraine • Respiratory Diseases • Urticaria

Rimegepant for the Prevention of Episodic Migraine in Adults with Prior Inadequate Response to Oral Preventatives: Results from a 12-week Open-label Extension Phase of a Randomized, Placebo-controlled Trial (AAN 2026) - P4 | "Rimegepant is well tolerated and reduces overall disease burden when taken for the prevention of migraine in participants with a documented history of prior inadequate response to OPMs. NCT05518123"

Clinical • CNS Disorders • Infectious Disease • Influenza • Migraine • Pain • Respiratory Diseases

Time Course of Effectiveness of Two Rimegepant Dosing Regimens for the Prevention of Episodic Migraine (AAN 2026) - P4 | "Both RIM regimens were effective for the preventive treatment of migraine within the first week with efficacy generally maintained through 12 weeks. Clinicaltrials.gov NCT05217927. Funded by Pfizer."

CNS Disorders • Migraine • Pain

Patient-reported Outcomes Through 12-weeks of Double-blind Rimegepant Treatment for the Prevention of Episodic Migraine in Adults with Prior Inadequate Response to Oral Preventatives (AAN 2026) - P4 | "Rimegepant 75 mg ODT EOD is associated with reductions in disease burden when taken for the prevention of EM for 12 weeks in participants with documented prior inadequate response to 2-4 categories of non-migraine specific OPM. NCT05518123"

Clinical • Patient reported outcomes • CNS Disorders • Migraine • Pain

Early Experience Treating Vestibular Migraine With Small Molecule CGRP Antagonists. (PubMed, Otolaryngol Head Neck Surg) - "Gepants are well-tolerated by patients and are promising agents for the treatment of vestibular migraine."

Journal • CNS Disorders • Migraine • Otorhinolaryngology • Pain • Vertigo

C4951063: A Study to Learn About the Study Medicine Called Rimegepant in Women When Used for Intermittent Prevention of Menstrual Migraine (clinicaltrialsregister.eu) - P2/3 | N=96 | Recruiting | Sponsor: Pfizer Inc.

New P2/3 trial • CNS Disorders • Migraine • Pain